US Capital Global Securities Advises on Multi-Million Dollar Debt Financing for the Treatment of Alzheimer’s and Parkinson’s
https://www.uscapital.com/transactions.php#neuroscience
Global private financial group for the middle market supports breakthrough company focusing on the diagnosis and treatment of severe neurodegenerative diseases.
SAN FRANCISCO, FEBRUARY 2024 – US Capital Global Securities LLC, an SEC-registered affiliate of US Capital Global, is pleased to announce that it has provided customized financial advisory services for a multi-million-dollar convertible note offering for a US-based innovator in biomarker testing for brain diseases (referred to as the “Company”). The Company specializes in early diagnosis and drug development for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Lewy Body Dementia.
With offices in San Francisco, Dallas, Miami, New York, London, Milan, and Dubai, US Capital Global is a full-service private financial group with an established track record in investment banking, asset management, and capital formation services. All securities are offered by the group through its FINRA-member, SEC-registered broker-dealer affiliate, US Capital Global Securities LLC.
“We are delighted to have provided customized financial advisory services for multi-million-dollar debt financing for this innovator in neuroscience,” said Charles Towle, CEO at US Capital Global Securities. “We are seeing a significant rise in the global diagnostics market, with an estimated market total this year standing at $280 billion and neurodegenerative disorders being the fastest growing segment within that. With strong projected growth in the next three years and an impressive global IP portfolio, the Company required additional financing to support its growth plans and bring its innovative products to market. We are extremely pleased to have advised the Company at this important inflection point in its growth.”
About US Capital Global
US Capital Global Securities LLC (USCGS) is the FINRA-member broker-dealer division of US Capital Global that acts as placement agent for growth-stage companies, projects, and investment funds. Since 1998, US Capital Global has been committed to providing lower middle market businesses and investors with sophisticated debt, equity, and investment opportunities usually available only to larger middle market companies and institutional investors, using the latest FinTech and RegTech innovation. US Capital Global entities manage direct investment funds and provide wealth management and capital raise services. USCGS or its affiliates may provide advice to, be compensated by, may have other business relationships with, or may from time to time acquire, hold, or sell a position in the securities of the issuers mentioned herein. Any such offer or solicitation shall be made only pursuant to the confidential private placement memorandum. View USCGS’ Form CRS at www.uscapglobalsecurities.com/crs.html.
To learn more about US Capital Global Securities and its services, email Charles Towle, CEO, at charles@uscapital.com or call +1 415-889-1010.
